Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
- 1 August 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 18 (8), 1470-1479
- https://doi.org/10.1002/ibd.21896
Abstract
Vedolizumab is a gut-selective biologic that has shown efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We studied the pharmacokinetics, pharmacodynamics, safety, tolerability, and efficacy of a new formulation of vedolizumab produced by an improved manufacturing process. UC patients were randomized to receive vedolizumab (2, 6, or 10 mg/kg) or placebo on days 1, 15, 29, and 85. Safety, pharmacokinetics, pharmacodynamics, and immunogenicity evaluations were performed at multiple timepoints through day 253. Partial Mayo Scores and fecal calprotectin levels were used to assess efficacy. In all, 46 patients (9 placebo, 37 vedolizumab) received at least one dose of study medication. The vedolizumab serum concentration declined monoexponentially until concentrations reached 1-10 μg/mL, and then fell nonlinearly. Vedolizumab maximum serum concentration (C(max) ) and area under the curve (AUC) increased approximately proportionally as a function of dose. Vedolizumab maximally saturated α(4) β(7) receptors on peripheral serum lymphocytes at all measurable serum concentrations. Vedolizumab was well tolerated, with no deaths and no adverse events leading to discontinuation. At every assessment from day 29 through day 253, over 50% of vedolizumab-treated patients were in clinical response, while placebo response rates generally ranged between 22% and 33%. Vedolizumab treatment reduced fecal calprotectin levels compared with placebo. Vedolizumab demonstrated dose-proportional pharmacokinetics and maximally saturated α(4) β(7) receptors over the tested dose range. Multiple dosing up to 10 mg/kg was well tolerated. Over the course of follow-up a greater proportion of patients treated with vedolizumab were in clinical response than those who were assigned to placebo.Keywords
This publication has 23 references indexed in Scilit:
- Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodiesTrends in Biotechnology, 2010
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabNew England Journal of Medicine, 2009
- Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together?: How to use immunosuppressive therapy better (and safer) tomorrow?Gastroentérologie Clinique et Biologique, 2009
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesJournal of Pharmacology and Experimental Therapeutics, 2009
- Immunotoxicity profile of natalizumabJournal of Immunotoxicology, 2009
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- A simple method for assessing intestinal inflammation in Crohn's diseaseGut, 2000
- Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker ProteinDigestion, 1997
- Assessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic StudyScandinavian Journal of Gastroenterology, 1992